The Institute of Molecular and Cell Biology (IMCB) was launched on 23 January 1985, with the official opening ceremony held on 2 October 1987 at the National University of Singapore (NUS), to develop and support the biomedical R&D capabilities in Singapore. It subsequently became an autonomous research institute (RI) of A*STAR, moving to Biopolis in 2004.
IMCB’s original vision was to foster a vibrant research culture to enable cutting edge discoveries and nurture high-quality talent. The creation and development of IMCB has catalyzed the transformation of Singapore into an international hub for biomedical research, development & innovation by:
1. fostering the biomedical research culture in Singapore
2. placing Singapore onto global map of scientific excellence
3. training & recruiting capable people at all levels
4. facilitating the development of other research entities
Over the years, IMCB has:
1. trained more than 250 PhDs
2. recruited more than 800 PhDs from the international community
3. published over 2,000 research papers in top international peer-reviewed journals, with a yearly citation above 8,000 since 2012
4. established numerous collaborations with industrial, clinical & academic partners, both locally and internationally
Today, IMCB has established itself as a premier molecular and cell biology institute.
Our vision is to remain a premier molecular biology and cell institute with increasing focus on addressing the mechanistic basis of human diseases.
Our mission is to:
1. conduct cutting-edge discovery research in disease pathways
2. groom early career researchers to be future leaders in their fields
3. collaborate with medical & industry communities for research impact
IMCB's research focuses on 2 major areas: Discovery research and Translational research
IMCB Discovery research comprises 4 major themes:
1. Animal Models of Development & Disease
2. Cancer & Stem Cell Genetics & Genomics
3. Structural Biology & Drug Discovery
4. Cell Biology in Health and Disease
IMCB Translational research comprises 3 major areas:
1. Humanized Model Organisms for Human Diseases
2. Systems Approach for Disease Target Identification & Validation
3. Protein Engineering & Antibody Development for Diagnostics & Therapeutics
IMCB Research is supported by cutting-edge infrastructure and capabilities including:
1. Quantitative Proteomics
2. Humanized Mice
3. Mouse Models of Human Cancer
4. Protein Crystallography X-Ray
5. Zebrafish for Drug Metabolism & Toxicology
6. Advanced Molecular Histopathology
7. Imaging & Electron Microscopy
8. DNA Sequencing
9. Medicinal Chemistry & Drug Development
10. Genome-wide RNAi screens
11. Monoclonal Antibody
IMCB was awarded the Nikkei Prize 2000 for Technological Innovation in recognition of its growth into a leading international research centre and its collaboration with industry and research institutes worldwide. Sixteen IMCB Principal Investigators have received National Science and Technology Awards and Medals. The Institute continues to publish in renowned international journals and has more than 2,000 publications to its credit since 1987. IMCB has also trained more than 220 postgraduate students.
IMCB has numerous collaborations with industrial, translational clinical and academic partners both in Singapore and worldwide. Recent highlights include the licensing of DNA methylation technology to Hitachi Asia Ltd. for cancer diagnostics development, the collaboration with Merlion Pharmaceuticals for a drug discovery program, licensing of zebrafish (Danio rerio) genetic markers, licensing of microbial collections for drug screening, development of SARS and malaria diagnostic kits and licensing of several monoclonal antibodies.
IMCB strives to maintain the scientific excellence of PI-driven research and at the same time aims to promote collaborative team-based projects of medical and industrial relevance.